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Glucagon like peptideAbstract Diabetes resulting from both genetic and lifestyle factors causes high insulin deﬁciency or
its resistance. As hyperglycemia and decreased insulin secretion and/or its sensitivity appear to be
the primary defects associated with diabetes, available treatments focus on reducing those defects. A
novel approach of treatment is to target the incretin mimetic hormones, which are secreted by intes-
tinal cells in response to food intake, provoking glucose-dependent insulin secretion from the pan-
creas. Efﬁcacy and safety studies of dipetidyl peptidase inhibitors (DPP-IV), sitagliptin, vildagliptin
and linagliptin provide similar improvements in HbA1c levels when compared with metformin, sul-
fonylureas or glitazones without contributing to weight gain and hypoglycemia. Caution is required
when choosing the gliptin in people with renal or hepatic impairment and with a risk of pancreatitis.
The glucagon like peptide (GLP-1) analogues Exenatide and Liraglutide also have positive impact
on glycemic control especially when used as a combination therapy. Another upcoming approach is
using sodium-glucose co transporter two inhibitors in kidney, by exploring pathophysiology of
renal glucose re absorption in the proximal tubule.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.Introduction
Even though diabetes is not a new born disease with a history
since 1552 its prevalence is increasing day by day. As in otherdiseases newer drugs are getting added up and some become
outdated or withdrawn. Even the most commonly used oral
hypoglycemic agent (OHA) metformin is found to be ineffec-
tive in the long-term therapy for many patients. Sulfonylureas
are used in case of patients who are not responding to metfor-
min. But they can put patients at an increased risk of hypogly-
cemia, weight gain, heart attacks and strokes. Glitazones are
also associated with cardiovascular risks. To avoid such
pitfalls and to improve glycemic control with minimum side
effects new therapeutic approaches are developed. Dipeptidyl
peptidase (DPP)-4 inhibitors, which enhance postprandial lev-
els of the incretin hormones glucagon like peptide (GLP)-1
404 R.E. George, S. Josephand glucose-dependent insulinotropic polypeptide (GIP), are
newer therapeutic options with minimal side effects (Dicker,
2011).
The revised consensus algorithm accounts for the intro-
duction of incretin-based therapies into clinical practice.
The algorithm was authored in 2009 by the American Diabe-
tes Association and European Association for the Study of
Diabetes for the initiation and adjustment of therapy in Type
2 diabetes. The incretin hormones are gut borne and have
clinically meaningful effects on glucose homeostasis, particu-
larly in the postprandial period. So according to the algo-
rithm their use can be emphasized in cases of
hypoglycemia and increased body weight. Also 66% of the
b-cell response during post prandial period is due to the
incretin effect. The foundation of incretin-based therapies is
to target this newly recognized feature of diabetes pathophys-
iology, resulting in sustained and powerful glycemic control
and body weight control (Stonehouse et al., 2012; McIntosh
et al., 2005).
The incretins are peptide hormones released into the circula-
tion, in response to luminal nutrients, minutes after a meal. In
humans, the major incretins are glucagon-like peptide-1 (GLP-
1) secreted by the L cells in the ileum and colon and glucose-
dependent insulinotropic polypeptide (GIP) secreted by the K
cells in the duodenum. Hormonal effects on multiple organs
are found to be exhibited by bothGLP-1 andGIP and stimulate
insulin secretion in a glucose-dependent manner along with
appetite suppression and delayed gastric emptying. As a result
of these combined effects, signiﬁcant contribution has been
made for the control of postprandial glucose resulting in a better
glycemic control with relatively low risk of hypoglycemia.
(Prins, 2008) The incretins are predominant gut bornemediators
of insulin release, and GLP-1 deals with glucagon suppression.
GLP-1 represents a clinically better therapeutic option over
GIPas its insulinotropic effects are preserved in type 2DMwhile
GIPactivity is impaired (Fujioka, 2007).However both incretins
are rapidly inactivated in vivo by the enzyme DPP-IV. Two ap-
proaches considered to enhance the incretin effect in type 2 dia-
betes are to either administer GLP-1 receptor agonists that are
resistant to cleavage by DPP4 or to inhibit DPP4 enzyme
activity. These pharmacological approaches thereby effectively
increase the half-life and circulating levels of the incretins (Prins,
2008).
Incretin-analogue based therapies
Glucagon-like peptide 1 (GLP-1) analogues are the founda-
tion of incretin-based therapies and the main advantage is
that they can be used as monotherapy, or in combination
with other diabetic medications along with diet and exercise
in adults with type 2 DM (Chiniwala and Jabbour, 2011)
Emerging evidence suggests minimum risk of hypoglycemia
with incretin-based treatments except in combination with
insulin secretagogues. They also exhibit beneﬁcial effects
on cardiovascular and hepatic health, the central nervous
system, inﬂammation and sleep (Stonehouse et al., 2012)
The administration of incretin analogues resistant to cleav-
age by DPP4 was really appreciable. Two drugs exenatide
and liraglutide are clinically used now, given as subcutane-ous injection. Formulation developments are on going to
check whether long-acting once-weekly injections are possi-
ble. Exendin, the clinical formulation of exenatide is a po-
tent activator of the GLP-1 receptor with almost 50%
homology to GLP-1, while liraglutide maintains normal
activity at the GLP-1 receptor. Both are resistant to cleav-
age by DPP4 and have a long circulating half-life (Prins,
2008).
Dipeptidyl-peptidase IV inhibitors
Dipeptidyl-peptidase (DPP) IV is a ubiquitous enzyme that is
responsible for the inactivation of both incretin hormones
GLP-1 and GIP. DPP IV inhibitors are FDA approved oral
medications in type 2 diabetes, which inhibit dipeptidyl pepti-
dase-4 thereby increase circulating concentrations of incretin
hormones and provide glycemic control with improved islet
cell function (Pratley and Salsali, 2007) and by this mechanism
of action they allow GLP1 to stay in the body for longer time
which improves control of glucose as well as reduce appetite.
They help the pancreas to secrete insulin in glucose dependent
manner in post-prandial period and thereby reducing dra-
matic episodes of blood sugar spikes (Stonehouse et al.,
2012) Also they are well tolerated, carry a low risk of hypogly-
cemia and weight gain (Stonehouse et al., 2012; Pratley and
Salsali, 2007).
Another new approach is the use of sodium glucose co
transporter-2 inhibitors which are in the phase III studies for
the treatment of type 2 diabetes. Several speciﬁc SGLT2 inhib-
itors currently under development include dapagliﬂozin, cana-
gliﬂozin, empagliﬂozin, ipragliﬂozin and tofogliﬂozin. They
work independently and inhibit glucose re-absorption from
the glomerular ﬁltrate. Reduced renal threshold for glucose,
glycosuria and net calorie loss are the results. Trials regarding
long-term outcomes are ongoing (Isaji, 2007; Grempler et al.,
2012).
In the present article, we discuss the attributes of new treat-
ment strategies of diabetes and an attempt has been made to
compare and elaborate various aspects of incretin based ther-
apies including their efﬁcacy and adverse reactions focused on
GLP1 agonists and commonly used gliptins-vildagliptin, Sitag-
liptin and linagliptin.
Comparison of various efﬁcacy studies of Sitagliptin,
Vildagliptin and Linagliptin
A large number of clinical studies and extensive clinical expe-
rience demonstrate that gliptins provide unique therapeutic
beneﬁts that make them ideal for treatment of type 2 diabetes.
They are available in combination pills with Metformin. All
these medicines have been shown to signiﬁcantly reduce
HbA1c when used as monotherapy and in combination with
other traditional agents. But they are comparatively more
expensive. Several studies were designed and done to compare
these drugs with other OHAs to clarify their efﬁcacy in relation
to traditional agents. Various meta analysis were done to study
the safety issues also. They are found to be associated with
minimum side effects like headache, nausea as well as mild skin
reactions.
Monotherapy
Drug Duration (weeks) Number of subjects (N) Baseline HbA1c (%) Reduction in HbA1c (%)
Sitagliptin
100 mg (Hanefeld et al., 2007; Scott et al.,
2007; Barzilai et al., 2009) 100 mg &
200 mg (Raz et al., 2006)
12 555 7.7 0.6
743 7.8 0.8
24 123 7.8 0.7 (Elderly)
18 521 8.1 0.6 & 0.5, respectively
100 mg & 200 mg (Aschner et al., 2006) 24 741 8 0.8 & 0.9, respectively
50 mg (moderate renal insuﬃciency)
25 mg (severe insuﬃciency) (Chan et al.,
2008)
54 65 7.7 0.6
Vildagliptin
25 mg BD vs Placebo (Pratley et al., 2006) 12 70 & 28, respectively 8 0.6 ± 0.2
50 mg BID, 50 mg OD & 100 mg OD
(Dejager et al., 2007)
24 632 8.4 0.8 ± 0.1,0.8 ± 0.1 &
0.9 ± 0.1, respectively
50 mg BID,50 mg OD & 100 mg OD (Pi-
Sunyer et al., 2007)
24 354 8.4 0.7 ± 0.2, 0.5 ± 0.2 &
0.9 ± 0.2, respectively
50 mg & 100 mg (Kalra, 2011) 12 279 & 98 8 0.43 & 0.6, respectively
10 mg, 25 mg & 50 mg BID vs Placebo
(Kikuchi et al., 2009)
12 291 7.4 0.8%, 1.0% & 1.2%
respectively (placebo
adjusted mean change)
50 mg BID compared with voglibose
(Iwamato et al., 2010)
12 188 & 192, respectively 7.6 <6.5% in 50.8% & 24.2%
patients respectively
100 mg compared with rosiglitazone 8 mg
(Rosenstock et al., 2007a)
24 519 & 267, respectively 8.7 1.1 & 1.3, respectively
Linagliptin
5MG vs Placebo (Del Prato et al., 2011) 24 336 & 167, respectively P 9.0 1.01% (placebo adjusted
reduction)
5 mg OD &10 mg OD vs voglibose 0.2 mg
tid (Kawamori et al., 2012)
26 561 7.63,7.50 & 7.91,
respectively
0.32% & 0.39%,
respectively (adjusted
mean diﬀerence)
5 mg OD &10 mg OD vs Placebo
(Kawamori et al., 2012)
12 – 7.58%, 7.48% and
8.34%, respectively
0.87% & 0.88%
respectively (adjusted
mean diﬀerence)
As add on to metformin
Sitagliptin
100 mg + metformin 2G BD,
100 mg + metformin 1G BD, metformin
2G BD, metformin 1G BD, 100 mg OD &
placebo (Goldstein et al., 2007)
24 1091 8.8 2.07%, 1.57%, 1.30%,
0.99% & 0.83%,
respectively (placebo
subtracted change)
100 mg vs Placebo (Charbonnel et al.,
2006)
24 701 8 <7% in 47% & 18.3%
patients respectively
100 mg vs 5 mg (Glipizide) (Nauck et al.,
2007)
52 1172 7.5 0.67 in both (63% and
59% patients respectively)
100 mg vs 8 mg (Rosiglitazone) (Scott
et al., 2008)
18 273 7.7 0.7 & 0.8, respectively
100 mg (As add on to
metformin + glimepiride) (Hermansen
et al., 2007)
24 441 8.3 0.89
Vildagliptin
50 mg OD (Ahren et al., 2004) 12 107 7.7 ± 0.1 0.6 ± 0.1
50 mg OD vs placebo (Ahren et al., 2005) 52 31& 26, respectively 7.7 1.0 ± 0.2% (between
group diﬀerence)
50 mg OD & 50 mg BID vs Placebo (Bosi
et al., 2007)
24 n= 177, 185 and 182,
respectively
7.5–11% 0.7 ± 0.1% &
1.1 ± 0.1%, respectively
(between group diﬀerence)
50 mg BID vs 30 mg OD pioglitazone
(Bolli et al., 2008)
24 295 & 281, respectively 7.5–11% 0.9 & 1.0, respectively
Linagliptin
Compared with Placebo (Taskinen et al.,
2011)
24 524 & 177, respectively 8.1 0.49 & +0.15, respectively
Compared with glimepiride (Gallwitz
et al., 2012a)
2 year 777 & 775, respectively 7.69 0.16 & 0.36, respectively
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Monotherapy
Drug Duration (weeks) Number of subjects (N) Baseline HbA1c (%) Reduction in HbA1c (%)
(As add on to metformin ± OAD) 1 mg,
5 mg, 10 mg vs Glimepiride (1–3 mg) or
Placebo (Forst et al., 2010)
12 333 8.2%, 8.5%, 8.4%,
8.2%, and 8.4%,
respectively
0.4,0.73,0.67 & 0.9
respectively (treatment
diﬀerence vs placebo)
(As add on to metformin + sulfonylurea)
5 mg vs Placebo (Owens et al., 2011)
24 793 & 265, respectively 7–10% 0.72 & 0.1, respectively
As add on to sulfonylurea
Sitagliptin
100 mg (Hermansen et al., 2007) 6 MONTH 441 8.3 0.7
Vildagliptin
50 mg OD, BID vs 4 mg
(Glimepiride + Placebo) (Garber et al.,
2008)
24 515 7.5–11 0.6 ± 0.1%, &
0.7 ± 0.1%, respectively
(between group diﬀerence)
Linagliptin
5 mg OD vs Placebo (Lewin et al., 2010) 18 161 & 84, respectively 8.6 0.47 (Placebo adjusted
change)
As add on to glitazones
Sitagliptin
Compared with placebo (Rosenstock
et al.)
24 175 & 178, respectively 8.1 & 8, respectively 7.2 & 7.8, respectively
(HbA1c at end point)
Vildagliptin
50 mg OD, BD vs 45 mg
Pioglitazone + Placebo (Garber et al.,
2007)
24 463 8.7 0.8, 1.0 & 0.3, respectively
100 mg OD vs 30 mg Pioglitazone OD)
(Rosenstock et al., 2007b
24 150 & 157, respectively 8.7 1.1 & 1.4, respectively
100 mg + 30 mg Pioglitazone &
50 mg + 15 mg Pioglitazone (Rosenstock
et al., 2007b)
24 146 & 139, respectively 8.7 1.9 & 1.7, respectively
Linagliptin
5 mg or Placebo (Gomis et al., 2011) 24 259 & 130, respectively 8.6 & 8.58, respectively 1.25 & 0.75, respectively
Comparison of safety studies
Drug Body weight Hypoglycemia More reported events Rare events
Sitagliptin Neutral (monotherapy)
Increasing (With
insulin and
sulfonylureas) (Scott
et al., 2007; Raz et al.,
2006; Rosenstock
et al., 2007a;
Charbonnel et al.,
2006; Hermansen et al.,
2007; Arjona Ferreira
et al., 2008)
None (monotherapy)
(Barzilai et al., 2009; Raz
et al., 2006; Rosenstock
et al., 2007a; Rosenstock
et al.)
Increasing (with insulin
and sulfonylureas)
(Nauck et al., 2007;
Hermansen et al., 2007;
Vilsboll et al., 2010)
Headache, upper
respiratory tract
infection,
nasopharyngitis. (Chan
et al., 2008)
Pancreatitis,
hypersensitivity reactions
(Ahre´n, 2010)
Vildagliptin Neutral (Bosi et al.,
2007; Bolli et al., 2008;
Garber et al., 2007;
Pratley et al., 2006;
Scherbaum et al., 2008;
Schweizer et al., 2007)
None (monotherapy)
Increasing (with insulin)
Kalra, 2011
Nausea, headache
nasopharyngitis,
dizziness, cough,
constipation (Pratley
et al., 2006; Scherbaum
et al., 2008)
Mild liver enzyme
elevation (Kothny et al.,
2009)
Linagliptin Neutral or decreased
(monotherapy) Del
Prato et al., 2011;
Taskinen et al., 2011;
Forst et al., 2010;
Owens et al., 2011;
Lewin et al., 2010;
Kawamori et al., 2011
Increasing (with
glitazones) Gomis
et al., 2011
Increasing (with insulin,
sulfonylureas and insulin
secretagogues) (Forst
et al., 2010; Owens et al.,
2011; Lewin et al., 2010;
Gallwitz et al., 2011)
Urticaria, angioedema
or bronchial
hyperreactivity (Del
Prato et al., 2011;
Taskinen et al., 2011;
Forst et al., 2010;
Owens et al., 2011;
Gomis et al., 2011;
Tradjenta, 2011)
-
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activity of incretins, the natural glucoregulatory peptides. In
April 2005 it was approved by the US FDA as an adjunctive
therapy in patients with type 2 diabetes. Exenatide is a subcu-
taneously injected, peptide GLP-1 receptor agonist that has
been shown to improve glycemic control, promote weight loss,
and improve some cardiovascular risk markers in patients with
T2DM (Klonoff et al., 2008; Aroda and DeYoung, 2011).
LIRAGLUTIDE: Liraglutide is another glucagon-like-pep-
tide-1 (GLP-1) receptor agonist, taken as once daily injection.
It was approved by FDA on January 25, 2010. It is designed
not only to improve 24-h glycemic control in a glucose-Monotherapy
Dose Duration
Exenatide
2 mg once weekly vs 100 mg Sitagliptin or 45 mg
Pioglitazone (Bergenstal et al., 2012)
26
Once weekly vs metformin, pioglitazone and Sitagliptin
(Jones et al., 2012) 26
Liraglutide
1.2 mg & 1.8 mg vs Glimepiride (Garber et al., 2009) 52
1.2 mg & 1.8 mg vs Glimepiride 8 mg (Garber et al., 2011) 2 year
0.65 mg, 1.25 mg, 1.90 mg & Placebo (Vilsboll et al., 2007) 14
As combination therapy
Exenatide
10 lg, 5 lg, and placebo (as add on to sulfonyl urea) (Buse
et al., 2004)
30
10 lg, 5 lg, and placebo (as add on to metformin)
(DeFronzo et al., 2005)
30
10 lg, 5 lg, and placebo (as add on to metformin &
sulfonylurea) (Kendall et al., 2005)
30
Liraglutide
1.8 mg & 1.2 mg (as add on to metformin, vs sitagliptin)
(Pratley et al., 2010)
26
(As add on to metformin + Rosiglitazone vs placebo)
(Zinman et al., 2009)
26
(As add on to metformin + glimepiride, vs insulin
glargine) (Russell-Jones et al., 2009)
26
(As add on to metformin + sulfonyl urea, vs exenatide)
(Buse et al., 2009)
26
Comparison of safety studies
Drug Body weight Hypoglycemia
Exenatide Decreased (Bergenstal et al.,
2012; Gallwitz et al., 2012b)
Mild episodes (Bergenstal
2012; Buse et al., 2004)
Liraglutide Neutral or decreased (Pratley
et al., 2010; Zinman et al., 2009;
Russell-Jones et al., 2009; Nauck
et al., 2009; Marre et al., 2009)
None Garber et al., 2009;
Zinman et al., 2009;
Buse et al., 2009; Nauck e
2009; Marre et al., 2009;
Seino et al., 2010; Kaku e
2010dependent manner by increasing insulin secretion and
decreasing glucagon secretion (Chang et al., 2003; Degn
et al., 2004) but also accompanied by a delay in gastric
emptying and weight loss (Juhl et al., 2002).
Many researchers have demonstrated that both exenatide
and liraglutide are well tolerated and produce clinically mean-
ingful reduction of HbA1c when used alone and in combina-
tion with other drugs.
Comparison of various efﬁcacy studies of exenatide and
liraglutideNo. of patients Reduction in HbA1c (%)
160, 166 & 165,
respectively
0.6 & 0.3, respectively (treatment
diﬀerence of exenatide vs Sitagliptin or
Pioglitazone)
– 1.53, 1.48, 1.63 & 1.15, respectively
746 0.84%, 1.14% & 0.51%, respectively
– 0.9, 1.1 & 0.6, respectively
– 0.98, 1.40, 1.45 & +0.29, respectively
377 0.86 ± 0.11%, 0.46 ± 0.12%, and
0.12 ± 0.09%, respectively
272 0.78 ± 0.10, 0.40 ± 0.11 &
+0.08 ± 0.10
733 0.8 ± 0.1, 0.6 ± 0.1 & +0.2 ± 0.1,
respectively
225,221 & 219,
respectively
1.5 & 1.24, respectively vs 0.9
533 1.5%± 0.1%vs 1.5%± 0.1%
581 1.33% vs 1.09%
233 & 231,
respectively
1.12% vs 0.79%, respectively
More reported events Rare events
et al., Nausea, diarrhea and upper-
respiratory-tract infection
(Bergenstal et al., 2012; Gallwitz
et al., 2012b)
Injection-site erythema,
pruritus, urticaria and
rash (Buse et al., 2004)
t al.,
t al.,
Nausea, vomiting, diarrhea and
constipation (Garber et al., 2009;
Pratley et al., 2010; Zinman et al.,
2009; Russell-Jones et al., 2009;
Nauck et al., 2009; Marre et al.,
2009; Seino et al., 2010; Kaku
et al., 2010)
Acute pancreatitis and
increase in calcitonin
level (Russell-Jones
et al., 2009; Nauck et al.,
2009; Marre et al., 2009)
408 R.E. George, S. JosephSodium glucose co-transporters 2 (SGLT2) inhibitors
They represent a new strategy in the treatment of diabetes with
a unique mechanism of action. They promote urinary glucose
excretion by inhibiting glucose reabsorption from renal tubules
and thus decrease plasma glucose levels. A signiﬁcant propor-
tion of glucose reabsorption is facilitated by SGLT-2, a mem-
ber of the SGLT family and other members include SGLT-1,
3, 4, 5, and 6. Inhibition of SGLT-2 has been shown to block
the body’s capacity to reabsorb glucose via the kidney and
thereby reduce blood glucose levels (Isaji, 2007).
The roles of other SGLT family members in glycemic con-
trol are not well understood. SGLT-1 is highly expressed in the
heart and also has an important role in normal intestinal glu-
cose absorption. But its inhibition may lead to diarrhea and se-
vere dehydration, symptoms observed in those with inherited
mutations in the SGLT-1 gene. SGLT-3 is expressed in neu-
rons of the small intestine and in neuromuscular junctions of
skeletal muscle, transports sodium upon glucose binding, but
not capable of monosaccharide transport. SGLT-4, 5 and 6
are expressed in the kidney and play an important role in renal
monosaccharide and/or sodium reabsorption (Grempler et al.,
2012).
SGLT-2 inhibitors fall into 2 classes. C-glucosides (empa-
gliﬂozin, dapagliﬂozin, canagliﬂozin, ipragliﬂozin and tofogli-
ﬂozin) and O-glucosides (sergliﬂozin, remogliﬂozin, T-1095A
and phlorizin). All SGLT inhibitors are structurally similar,
with different selectivity proﬁle. Among the inhibitors tested
for SGLT-2 over SGLT-1, Empagliﬂozin was shown to have
the highest selectivity with fewer gastrointestinal side effects
than the other less selective SGLT-2 inhibitors (Grempler
et al., 2012). Preclinical studies and clinical trials have revealed
that SGLT2 inhibition offers beneﬁts to diabetic patients by
reducing plasma glucose levels, decreasing glucotoxicity and
lowering glycosylated hemoglobin levels. Some studies of
O-glucosides showed unfavorable pharmacokinetic proﬁle
too. The therapeutic potential and safety concerns of these
new drugs are currently under clinical development.
Summary and discussion
All the people never respond in the same way to treatments.
Innovative and safe options with better treatment outcomes
are greatly needed for the current generation of patients
worldwide who are struggling with glycemic control problems,
cardiovascular issues and obesity. Traditional oral anti-
diabetic drugs achieve only limited glycemic control and are
accompanied by weight gain or hypoglycemia except for bigu-
anides and alpha-glycosidase inhibitors. Many randomized,
double-blind, placebo or active comparator controlled, multi-
centre trials in patients with T2DM have proved that gliptins
produce clinically meaningful reduction of HbA1c and are well
tolerated in patients who are inadequately controlled with
Metformin, sulfonylureas or glitazones or even with insulin.
Unique mechanism of action and oral dosing certainly po-
sition gliptins to be a ﬁrst line option. But high cost and rel-
ative lack of long-term safety and efﬁcacy studies like impact
on cardiovascular disease are the major constraints at this
point. Data from clinical trials suggest that one gliptin is
not superior over another with regard to efﬁcacy. But partic-
ularly some factors have to be in mind for safe use of eachgliptin. Renal function assessment is needed prior to initiat-
ing and periodically during the treatment with sitagliptin. A
dosage adjustment is recommended in moderate or severe re-
nal insufﬁciency and in end-stage renal disease and dialysis
cases (Ahre´n, 2010) Also observe patients carefully for signs
and symptoms if pancreatitis or a hypersensitivity reaction
is suspected. The important clinical concern with vildagliptin
is liver enzyme monitoring before and after its initiation since
some hepatic enzyme elevation cases were reported with the
vildagliptin therapy. While initiating linagliptin, one should be
aware of the potential risk for acute pancreatitis (Tradjenta,
2011) Investigators have examined the use of linagliptin in
patients with compromised renal function (Sloan et al., 2011;
Graefe-Mody et al., 2011) and concluded that dose adjust-
ments based on renal function are not required. Exenatide
and liraglutide are subcutaneously injected, peptide GLP-1
receptor agonists that have been shown to improve glycemic
control, promote weight loss, and improve some cardiovascu-
lar risk markers in patients with T2DM (Klonoff et al., 2008;
Aroda and DeYoung, 2011).References
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